前列腺癌相关标志物的研究进展  

The progress of biomarkers in prostate cancer

作　　者：段秀枝[1] 陶志华[1] 

机构地区：[1]浙江大学医学院附属第二医院检验科,杭州310009

出　　处：《中华检验医学杂志》2015年第10期657-660,共4页Chinese Journal of Laboratory Medicine

基　　金：基金项目：国家自然科学基金（81271917）;浙江省自然科学基金（LY15H200002）

摘　　要：受环境及生活方式转变等多因素的影响，前列腺癌成为老年男性常见的恶性肿瘤。血清前列腺特异性抗原的广泛应用，显著改变了前列腺癌的诊断和治疗。然而，作为前列腺癌筛选指标的前列腺特异抗原检测导致的前列腺癌患者过度诊治引起了学术界较大争议，另其在前列腺癌预测、治疗以及辅助临床决策的准确性也存在缺陷。因此，临床迫切需要新标志物来补充前列腺癌的监测和管理。本文对前列腺癌早期诊断及预后监测方面的新标志物进行了概括阐述，以期为前列腺癌的临床诊断及预后评估提供参考依据。Affected by many factors such as environment and lifestyle change, prostate cancer has become common malignancy in older men. The introduction and widespread adoption of PSA has revolutionized the way prostate cancer is diagnosed and treated. However, the use of PSA has also led to over-diagnosis and overtreatment of prostate cancer resulting in controversy about its use for screening. PSA also has limited predictive accuracy for predicting outcomes after treatment and for making clinical decisions about adjuvant and salvage therapies. Hence, there is an urgent need for novel biomarkers to supplement PSA for detection and management of prostate cancer. In this review, we discuss the traditional and new relevant molecular markers of early diagnosis and prognosis of prostate cancer for clinical diagnosis and prognosis of prostate cancer providing a reference.

关 键 词：前列腺肿瘤 早期诊断 肿瘤标记 生物学 预后 

分 类 号：R737.25[医药卫生—肿瘤]